Literature DB >> 23999787

Role of preprocedural computed tomography in transcatheter aortic valve implantation.

L Lehmkuhl1, B Foldyna, M Haensig, K von Aspern, C Lücke, C Andres, M Grothoff, F Riese, S Nitzsche, D Holzhey, A Linke, F-W Mohr, M Gutberlet.   

Abstract

UNLABELLED: Transcatheter aortic valve implantation (TAVI) is currently considered an acceptable alternative for the treatment of patients with severe aortic stenosis and a high perioperative risk or a contraindication for open surgery. The benefit of TAVI significantly outweighs the risk of the procedure in patients requiring treatment that are not suitable for open surgery, and leads to a lower mortality in the one-year follow-up. The absence of a direct view of the aortic root and valve remains a challenge for the transcatheter approach. While direct inspection of the aortic valve during open surgery allows an adequate prosthesis choice, it is crucial for TAVI to know the individual anatomical details prior to the procedure in order to assure adequate planning of the procedure and proper prosthesis choice and patient selection. Among the imaging modalities available for the evaluation of patients prior to TAVI, computed tomography (CT) plays a central role in patient selection. CT reliably visualizes the dimensions of the aortic root and allows a proper choice of the prosthesis size. The morphology of the access path and relevant comorbidities can be assessed. The present review summarizes the current state of knowledge regarding the value of CT in the evaluation of patients prior to TAVI. KEY POINTS: CT plays a central role in patient selection and planning prior to TAVI. ▶ CT reliably detects the dimensions of the aortic root including the size of the aortic annulus, the degree of valve calcification and the morphology of the access routes. ▶ CT provides a more accurate measurement of the aortic annulus than 2D TEE and CT is the only imaging modality that allows a risk assessment for paravalvular leakages based on the calcification of the aortic valve. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23999787     DOI: 10.1055/s-0033-1350416

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  6 in total

1.  CT evaluation prior to transapical aortic valve replacement: semi-automatic versus manual image segmentation.

Authors:  Borek Foldyna; Camelia Jungert; Christian Luecke; Konstantin von Aspern; Sonja Boehmer-Lasthaus; Eva Maria Rueth; Matthias Grothoff; Stefan Nitzsche; Matthias Gutberlet; Friedrich Wilhelm Mohr; Lukas Lehmkuhl
Journal:  Int J Cardiovasc Imaging       Date:  2015-04-19       Impact factor: 2.357

Review 2.  Transcatheter aortic valve replacement with a focus on transcarotid: a review of the current literature.

Authors:  Issa Pour-Ghaz; Joel Raja; Mahmoud Bayoumi; Theodore Manolukas; Rami N Khouzam; Uzoma N Ibebuogu
Journal:  Ann Transl Med       Date:  2019-09

3.  MDCT evaluation of aortic root and aortic valve prior to TAVI. What is the optimal imaging time point in the cardiac cycle?

Authors:  Tomas Jurencak; Jakub Turek; Bastiaan L J H Kietselaer; Casper Mihl; Madeleine Kok; Vincent G V A van Ommen; Leen A F M van Garsse; Estelle C Nijssen; Joachim E Wildberger; Marco Das
Journal:  Eur Radiol       Date:  2015-02-24       Impact factor: 5.315

4.  Imaging of cardiac valves by computed tomography.

Authors:  Gudrun Feuchtner
Journal:  Scientifica (Cairo)       Date:  2013-12-29

5.  Transcatheter aortic valve replacement in patients with previous mitral valve replacement. A systematic study.

Authors:  Zbigniew Chmielak; Maciej Dąbrowski; Paweł Tyczyński; Krzysztof Kukuła; Ilona Michałowska; Emilia Szudejko; Jarosław Skowroński; Mariusz Kuśmierczyk; Adam Witkowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2020-06-23       Impact factor: 1.426

6.  Better survival after transcatheter aortic valve replacement by process improvements.

Authors:  G J van Steenbergen; D van Veghel; D N Schulz; M Soliman-Hamad; P A Tonino; S Houterman; L Dekker
Journal:  Neth Heart J       Date:  2020-12-07       Impact factor: 2.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.